To purchase hard copies of this book, please email:
orders@intechopen.com
By only printing on demand InTech ensures our carbon footprint is kept to a minimum.
The data below shows the environmental impact of printing one single book:
67.53 kg wood
3.63 g CO2
61.32 ml Water
Share this page
Dyslipidemia - From Prevention to Treatment
Edited by Roya Kelishadi, ISBN 978-953-307-904-2, Hard cover, 468 pages, Publisher: InTech, Published: February 03, 2012 under CC BY 3.0 license, in subject Endocrinology and Metabolism
DOI: 10.5772/1182
Dyslipidemia has a complex pathophysiology consisting of various genetic, lifestyle, and environmental factors. It has many adverse health impacts, notably in the development of chronic non-communicable diseases. Significant ethnic differences exist due to the prevalence and types of lipid disorders. While elevated serum total- and LDL-cholesterol are the main concern in Western populations, in other countries hypertriglyceridemia and low HDL-cholesterol are more prevalent. The latter types of lipid disorders are considered as components of the metabolic syndrome. The escalating trend of obesity, as well as changes in lifestyle and environmental factors will make dyslipidemia a global medical and public health threat, not only for adults but for the pediatric age group as well. Several experimental and clinical studies are still being conducted regarding the underlying mechanisms and treatment of dyslipidemia. The current book is providing a general overview of dyslipidemia from diverse aspects of pathophysiology, ethnic differences, prevention, health hazards, and treatment.
This book is indexed in:
Book contents
- Chapter 1Obesity Related Lipid Profile and Altered Insulin Incretion in Adolescent with Policystic Ovary Syndrome
- Chapter 2Ethnic Difference in Lipid Profiles
- Chapter 3Nutrigenetics and Dyslipidemia
- Chapter 4Impact of Climate Change and Air Pollution on Dyslipidemia and the Components of Metabolic Syndrome
- Chapter 5Dyslipidemia and Type 2 Diabetes Mellitus: Implications and Role of Antiplatelet Agents in Primary Prevention of Cardiovascular Disease
- Chapter 6Dyslipidemia: Genetics and Role in the Metabolic Syndrome
- Chapter 7Functions of OSBP/ORP Family Proteins and Their Relation to Dyslipidemia
- Chapter 8Adipose Tissue and Skeletal Muscle Plasticity in Obesity and Metabolic Disease
- Chapter 9Pleiotropic Functions of HDL Lead to Protection from Atherosclerosis and Other Diseases
- Chapter 10Disrupted VLDL Features and Lipoprotein Metabolism in Sepsis
- Chapter 11Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ) as a Potential Therapeutic Target for Dyslipidemia
- Chapter 12Liver Glucokinase and Lipid Metabolism
- Chapter 13Liver Sinusoidal Endothelial Cells and Regulation of Blood Lipoproteins
- Chapter 14Dyslipidemia and Cardiovascular Risk: Lipid Ratios as Risk Factors for Cardiovascular Disease
- Chapter 15Dyslipidemia and Cardiovascular Disease
- Chapter 16Cardiovascular Risk in Tunisian Patients with Bipolar I Disorder
- Chapter 17Dyslipidemia and Mental Illness
- Chapter 18Dyslipidemia Induced by Stress
- Chapter 19Cholesterol and Triglycerides Metabolism Disorder in Malignant Hemopathies
- Chapter 20Lipids in the Pathogenesis of Benign Prostatic Hyperplasia: Emerging Connections
- Chapter 21Dyslipidemia in Patients with Lipodystrophy in the Use of Antiretroviral Therapy
- Chapter 22Fenofibrate: Panacea for Aging-Related Conditions?
- Chapter 23Predictors of the Common Adverse Drug Reactions of Statins
